Cargando…

Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics

SIMPLE SUMMARY: Prostate cancer (PCa) is notoriously difficult to diagnose owing to the lack of reliable biomarkers and the invasiveness of obtaining a tissue biopsy from the prostate. As an alternative, we developed a liquid biopsy technique, based on isolating tumor cells from semen samples via a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rzhevskiy, Alexey S., Kapitannikova, Alina Y., Vasilescu, Steven A., Karashaeva, Tamilla A., Razavi Bazaz, Sajad, Taratkin, Mark S., Enikeev, Dmitry V., Lekarev, Vladimir Y., Shpot, Evgeniy V., Butnaru, Denis V., Deyev, Sergey M., Thiery, Jean Paul, Zvyagin, Andrei V., Ebrahimi Warkiani, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318520/
https://www.ncbi.nlm.nih.gov/pubmed/35884424
http://dx.doi.org/10.3390/cancers14143364
_version_ 1784755312199204864
author Rzhevskiy, Alexey S.
Kapitannikova, Alina Y.
Vasilescu, Steven A.
Karashaeva, Tamilla A.
Razavi Bazaz, Sajad
Taratkin, Mark S.
Enikeev, Dmitry V.
Lekarev, Vladimir Y.
Shpot, Evgeniy V.
Butnaru, Denis V.
Deyev, Sergey M.
Thiery, Jean Paul
Zvyagin, Andrei V.
Ebrahimi Warkiani, Majid
author_facet Rzhevskiy, Alexey S.
Kapitannikova, Alina Y.
Vasilescu, Steven A.
Karashaeva, Tamilla A.
Razavi Bazaz, Sajad
Taratkin, Mark S.
Enikeev, Dmitry V.
Lekarev, Vladimir Y.
Shpot, Evgeniy V.
Butnaru, Denis V.
Deyev, Sergey M.
Thiery, Jean Paul
Zvyagin, Andrei V.
Ebrahimi Warkiani, Majid
author_sort Rzhevskiy, Alexey S.
collection PubMed
description SIMPLE SUMMARY: Prostate cancer (PCa) is notoriously difficult to diagnose owing to the lack of reliable biomarkers and the invasiveness of obtaining a tissue biopsy from the prostate. As an alternative, we developed a liquid biopsy technique, based on isolating tumor cells from semen samples via a microfluidic device. To optimize the device, we first attempted to recover PCa cells from semen samples spiked with PCa cell lines, achieving an average efficiency of >87% cell recovery at the chosen flow rate. We then transitioned to a clinical setting using semen samples from PCa patients. The yield of isolated clinical PCa cells varied between 67 and 307 cells per mL of semen (in 15 cancer patients). These cells were stained and compared to the standard prognostic parameters such as Gleason score and PSA serum level. This study presents a potential liquid biopsy technique to augment the existing diagnosis and prognosis of PCa. ABSTRACT: Prostate cancer (PCa) diagnosis is primarily based on prostate-specific antigen (PSA) testing and prostate tissue biopsies. However, PSA testing has relatively low specificity, while tissue biopsies are highly invasive and have relatively low sensitivity at early stages of PCa. As an alternative, we developed a technique of liquid biopsy, based on isolation of circulating tumor cells (CTCs) from seminal fluid (SF). The recovery of PCa cells from SF was demonstrated using PCa cell lines, achieving an efficiency and throughput as high as 89% (±3.8%) and 1.7 mL min(−1), respectively, while 99% (±0.7%) of sperm cells were disposed of. The introduced approach was further tested in a clinical setting by collecting and processing SF samples of PCa patients. The yield of isolated CTCs measured as high as 613 cells per SF sample in comparison with that of 6 cells from SF of healthy donors, holding significant promise for PCa diagnosis. The correlation analysis of the isolated CTC numbers with the standard prognostic parameters such as Gleason score and PSA serum level showed correlation coefficient values at 0.40 and 0.73, respectively. Taken together, our results show promise in the developed liquid biopsy technique to augment the existing diagnosis and prognosis of PCa.
format Online
Article
Text
id pubmed-9318520
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93185202022-07-27 Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics Rzhevskiy, Alexey S. Kapitannikova, Alina Y. Vasilescu, Steven A. Karashaeva, Tamilla A. Razavi Bazaz, Sajad Taratkin, Mark S. Enikeev, Dmitry V. Lekarev, Vladimir Y. Shpot, Evgeniy V. Butnaru, Denis V. Deyev, Sergey M. Thiery, Jean Paul Zvyagin, Andrei V. Ebrahimi Warkiani, Majid Cancers (Basel) Article SIMPLE SUMMARY: Prostate cancer (PCa) is notoriously difficult to diagnose owing to the lack of reliable biomarkers and the invasiveness of obtaining a tissue biopsy from the prostate. As an alternative, we developed a liquid biopsy technique, based on isolating tumor cells from semen samples via a microfluidic device. To optimize the device, we first attempted to recover PCa cells from semen samples spiked with PCa cell lines, achieving an average efficiency of >87% cell recovery at the chosen flow rate. We then transitioned to a clinical setting using semen samples from PCa patients. The yield of isolated clinical PCa cells varied between 67 and 307 cells per mL of semen (in 15 cancer patients). These cells were stained and compared to the standard prognostic parameters such as Gleason score and PSA serum level. This study presents a potential liquid biopsy technique to augment the existing diagnosis and prognosis of PCa. ABSTRACT: Prostate cancer (PCa) diagnosis is primarily based on prostate-specific antigen (PSA) testing and prostate tissue biopsies. However, PSA testing has relatively low specificity, while tissue biopsies are highly invasive and have relatively low sensitivity at early stages of PCa. As an alternative, we developed a technique of liquid biopsy, based on isolation of circulating tumor cells (CTCs) from seminal fluid (SF). The recovery of PCa cells from SF was demonstrated using PCa cell lines, achieving an efficiency and throughput as high as 89% (±3.8%) and 1.7 mL min(−1), respectively, while 99% (±0.7%) of sperm cells were disposed of. The introduced approach was further tested in a clinical setting by collecting and processing SF samples of PCa patients. The yield of isolated CTCs measured as high as 613 cells per SF sample in comparison with that of 6 cells from SF of healthy donors, holding significant promise for PCa diagnosis. The correlation analysis of the isolated CTC numbers with the standard prognostic parameters such as Gleason score and PSA serum level showed correlation coefficient values at 0.40 and 0.73, respectively. Taken together, our results show promise in the developed liquid biopsy technique to augment the existing diagnosis and prognosis of PCa. MDPI 2022-07-11 /pmc/articles/PMC9318520/ /pubmed/35884424 http://dx.doi.org/10.3390/cancers14143364 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rzhevskiy, Alexey S.
Kapitannikova, Alina Y.
Vasilescu, Steven A.
Karashaeva, Tamilla A.
Razavi Bazaz, Sajad
Taratkin, Mark S.
Enikeev, Dmitry V.
Lekarev, Vladimir Y.
Shpot, Evgeniy V.
Butnaru, Denis V.
Deyev, Sergey M.
Thiery, Jean Paul
Zvyagin, Andrei V.
Ebrahimi Warkiani, Majid
Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title_full Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title_fullStr Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title_full_unstemmed Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title_short Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics
title_sort isolation of circulating tumor cells from seminal fluid of patients with prostate cancer using inertial microfluidics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318520/
https://www.ncbi.nlm.nih.gov/pubmed/35884424
http://dx.doi.org/10.3390/cancers14143364
work_keys_str_mv AT rzhevskiyalexeys isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT kapitannikovaalinay isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT vasilescustevena isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT karashaevatamillaa isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT razavibazazsajad isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT taratkinmarks isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT enikeevdmitryv isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT lekarevvladimiry isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT shpotevgeniyv isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT butnarudenisv isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT deyevsergeym isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT thieryjeanpaul isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT zvyaginandreiv isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics
AT ebrahimiwarkianimajid isolationofcirculatingtumorcellsfromseminalfluidofpatientswithprostatecancerusinginertialmicrofluidics